"Navigating the Modern News Zoo so you don't have to."
Wednesday, July 9, 2025
Data show teclistamab can benefit many multiple myeloma patients who would have been ineligible for pivotal trial
Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation antigen (BCMA) receptor. It received accelerated approval in 2022 for patients treated with four or more lines of prior therapy based on results from the Phase I/II MajesTEC-1 clinical trial.
đ Full Story
Mayor Busted: Nashville Mayor Investigation Intensifies For Leaking DHS Info!
- Revolutionizing Communication: DeWave Decodes Brain Activity into Text - Sean George
- Maynard Childrenâs Hospital partnership with Book Harvest provides books to newborns - Jerry.Grimes@ecuhealth.org
- Scaly situation! Alligator spotted outside motel room in Fairfax County
- The best Amazon Prime Day deals under $50: Save on gear from Samsung, Blink, Anker, and others - Amy Skorheim
- Microsoft Ignite 2023: Unveiling the Future of AI Transformation and Technological Revolution - Sean George
- TikTok Unveils New 'Add to Music App' Feature in Partnership with Major Music Streaming Services - Bertha Stephens
5 Common Retirement Habits to Avoid
- Nippon Steel, U.S. Steel Tie-Up Could Be A âGame Changerâ - Eric Laursen
- âThe Morning Showâ Teases âDrama At Network Is Juicier Than Drama On Networkâ For Season 4 - Lynette Rice
- Texas' Big Bend National Park Suffering Staff Shortages - or Is It?
- Google's Ambitious Gaming Venture: A Historical Look at their Attempt to Purchase Epic Games - Michael A. Medeiros
- Gmailâs new subscription management is here to declutter your inbox - Ryan Whitwam
- Best Amazon Prime Day 2025 deals: Our top picks on headphones, TVs, robot vacuums and more - Valentina Palladino
